Related Experiment Videos

Increased Th9 cells and IL-9 levels accelerate disease progression in experimental atherosclerosis

Qing Li1, Tingting Ming1, Yuanmin Wang2

  • 1The Central Laboratory of Medical Research Center, Anhui Provincial Hospital, Anhui Medical University Hefei 230001, Anhui, PR China.

Insights

This study reveals that Th9 cells and IL-9 significantly contribute to atherosclerosis development. Targeting these elements with antibodies may offer a new therapeutic strategy for this chronic inflammatory disease.

Area of Science:

  • Immunology
  • Cardiovascular Research
  • Inflammation Biology

Background:

  • Atherosclerosis (AS) is a leading cause of death globally, recognized as a chronic inflammatory condition.
  • T cells are implicated in AS pathogenesis, but the role of the Th9 subset remains unclear.

Purpose of the Study:

  • To investigate the role of Th9 cells and their associated cytokine, IL-9, in the development of atherosclerosis.
  • To assess Th9 cell populations, IL-9 levels, and the transcription factor PU.1 in a mouse model of AS.

Main Methods:

  • Quantification of Th9 cells, IL-9, and PU.1 in ApoE-/- mice (prone to atherosclerosis) versus C57BL/6J mice.
  • Administration of recombinant IL-9 (rIL-9) to assess its effect on AS progression.
  • Treatment with anti-IL-9 antibodies to evaluate therapeutic potential.

Main Results:

  • ApoE-/- mice exhibited significantly higher numbers of Th9 cells, elevated IL-9 levels, and increased PU.1 expression compared to control mice.
  • Exogenous rIL-9 exacerbated atherosclerotic lesion development.
  • Anti-IL-9 antibody treatment attenuated the progression of atherosclerosis.

Conclusions:

  • Th9 cells and IL-9 play a critical role in promoting the pathogenesis of atherosclerosis.
  • Targeting Th9 cells and IL-9 via antibody-based therapies presents a promising novel therapeutic avenue for AS treatment.

Related Concept Videos